Dr. Shah on Options for Ibrutinib-Intolerant Patients With MCL

Video

In Partnership With:

Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses a therapeutic option on the horizon for patients with mantle cell lymphoma (MCL) who are intolerant to ibrutinib (Imbruvica).

Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses a therapeutic option on the horizon for patients with mantle cell lymphoma (MCL) who are intolerant to ibrutinib (Imbruvica).

Shah poses the question: how are researchers going to succeed in this space of MCL in ibrutinib-intolerant patients? Though ibrutinib can be efficacious in select patients, it is a therapeutic challenge for patients who do not respond or in intolerant to the BTK inhibitor.

This is where chimeric antigen receptor (CAR) T-cell therapy has a very important role to play, Shah explains. This is being explored in a clinical trial by Kite Pharma, which is enrolling patients with MCL who are ibrutinib-intolerant. Thus far, there is very encouraging activity, he adds.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD